In hospitalized children on anticoagulants, automated trigger tools were relatively inefficient in finding adverse events.Jt Comm J Qual Patient Saf. 2015;41:108-114.
Monitoring the harm associated with use of anticoagulants in pediatric populations through trigger-based automated adverse-event detection.
Patregnani JT, Spaeder MC, Lemon V, Diab Y, Klugman D, Stockwell DC. Jt Comm J Qual Patient Saf. 2015;41:108-114.
Warfarin and other anticoagulant medications are known to place patients at high risk of adverse drug events across multiple settings. This retrospective study examined the safety of anticoagulant therapy in hospitalized children. Researchers used a trigger approach in which abnormal laboratory test values were used to identify medical records which were reviewed for the presence or absence of an adverse drug event, an approach that has been used in other settings. They also used the administration of a reversal agent, protamine, as a trigger to detect adverse drug events. Relatively few adverse events were identified in comparison to the high number of records screened. These findings underscore the need for more sophisticated automated rules to enhance trigger-based identification of adverse drug events. A past AHRQ WebM&M commentary discussed the hazards related to prescribing warfarin and best practices to reduce risks associated with anticoagulant use.
Optimization of drug–drug interaction alert rules in a pediatric hospital's electronic health record system using a visual analytics dashboard.
Simpao AF, Ahumada LM, Desai BR, et al. J Am Med Inform Assoc. 2014 Oct 15; [Epub ahead of print].
The impact of electronic medical records data sources on an adverse drug event quality measure.
Kahn MG, Ranade D. J Am Med Inform Assoc. 2010;17:185-191.
Preventing medication errors in hospitals through a systems approach and technological innovation: a prescription for 2010.
Crane J, Crane FG. Hosp Top. Fall 2006;84:3-8.
STUDYView all related resources...
Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
Ferranti J, Horvath MM, Cozart H, Whitehurst J, Eckstrand J. Pediatrics. 2008;121:e1201-e1207.